Late-onset cytomegalovirus disease in patients with solid organ transplant

Abstract

The best approach to prevent or manage late cytomegalovirus disease associated with cytomegalovirus prophylaxis remains to be defined.

Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation

“…Other humoral immunity or functional anti-CMV cellular defects [15][16][17] might explain development of CMV disease in D+/R+ patients, who showed normal titers of anti-CMV antibodies before and after HT. Some of these patients were found to have IgG hypogammaglobulinemia or IgG1 decreased levels.…”

Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study

“…Another possibility is the fact that prophylaxis was administered over a short period of time in comparison with what is recommended in other clinical trials and local guidelines (20). In fact, the apparent lack of control of CMV viremia is more likely to simply be late‐onset CMV disease, because the median time to positive viremia in the D+/R− patients was 77 days, which indicates that development of viremia more than likely occurred after discontinuation of prophylactic therapy (44).…”

Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients

“…Major risk factors associated with CMV disease are the CMV serostatus (donor positive, recipient negative [Dþ/RÀ] being at the highest risk), the type of organ transplanted and the immunosuppressive regimen used (3). CMV disease in this population presents with viral syndrome or tissue-invasive disease, which can be life-threatening if untreated.…”